Clover Health Investments Statistics
Total Valuation
CLOV has a market cap or net worth of $2.26 billion. The enterprise value is $2.06 billion.
| Market Cap | 2.26B |
| Enterprise Value | 2.06B |
Important Dates
The last earnings date was Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CLOV has 531.16 million shares outstanding. The number of shares has increased by 3.75% in one year.
| Current Share Class | 435.44M |
| Shares Outstanding | 531.16M |
| Shares Change (YoY) | +3.75% |
| Shares Change (QoQ) | +4.46% |
| Owned by Insiders (%) | 21.59% |
| Owned by Institutions (%) | 27.89% |
| Float | 412.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 58.85 |
| PS Ratio | 0.91 |
| Forward PS | 0.70 |
| PB Ratio | 5.98 |
| P/TBV Ratio | 6.05 |
| P/FCF Ratio | 30.46 |
| P/OCF Ratio | 29.34 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 27.78 |
Financial Position
The company has a current ratio of 1.50
| Current Ratio | 1.50 |
| Quick Ratio | 1.38 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -5.10% and return on invested capital (ROIC) is -3.19%.
| Return on Equity (ROE) | -5.10% |
| Return on Assets (ROA) | -1.77% |
| Return on Invested Capital (ROIC) | -3.19% |
| Return on Capital Employed (ROCE) | -4.62% |
| Weighted Average Cost of Capital (WACC) | 17.87% |
| Revenue Per Employee | $3.42M |
| Profits Per Employee | -$25,362 |
| Employee Count | 724 |
| Asset Turnover | 3.82 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +59.96% in the last 52 weeks. The beta is 2.48, so CLOV's price volatility has been higher than the market average.
| Beta (5Y) | 2.48 |
| 52-Week Price Change | +59.96% |
| 50-Day Moving Average | 4.51 |
| 200-Day Moving Average | 3.14 |
| Relative Strength Index (RSI) | 47.51 |
| Average Volume (20 Days) | 3,551,164 |
Short Selling Information
The latest short interest is 26.14 million, so 4.92% of the outstanding shares have been sold short.
| Short Interest | 26.14M |
| Short Previous Month | 28.24M |
| Short % of Shares Out | 4.92% |
| Short % of Float | 6.33% |
| Short Ratio (days to cover) | 5.70 |
Income Statement
In the last 12 months, CLOV had revenue of $2.48 billion and -$18.36 million in losses. Loss per share was -$0.04.
| Revenue | 2.48B |
| Gross Profit | 459.13M |
| Operating Income | -18.36M |
| Pretax Income | -18.36M |
| Net Income | -18.36M |
| EBITDA | -17.96M |
| EBIT | -18.36M |
| Loss Per Share | -$0.04 |
Balance Sheet
The company has $243.10 million in cash and no debt, with a net cash position of $198.84 million or $0.37 per share.
| Cash & Cash Equivalents | 243.10M |
| Total Debt | n/a |
| Net Cash | 198.84M |
| Net Cash Per Share | $0.37 |
| Equity (Book Value) | 376.26M |
| Book Value Per Share | 0.71 |
| Working Capital | 162.12M |
Cash Flow
In the last 12 months, operating cash flow was $77.03 million and capital expenditures -$2.83 million, giving a free cash flow of $74.21 million.
| Operating Cash Flow | 77.03M |
| Capital Expenditures | -2.83M |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | 74.21M |
| FCF Per Share | $0.14 |
Margins
Gross margin is 18.54%, with operating and profit margins of -0.74% and -0.74%.
| Gross Margin | 18.54% |
| Operating Margin | -0.74% |
| Pretax Margin | -0.74% |
| Profit Margin | -0.74% |
| EBITDA Margin | -0.73% |
| EBIT Margin | -0.74% |
| FCF Margin | 3.00% |
Dividends & Yields
CLOV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.75% |
| Shareholder Yield | -3.75% |
| Earnings Yield | -0.81% |
| FCF Yield | 3.28% |
Analyst Forecast
The average price target for CLOV is $5.17, which is 21.50% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.17 |
| Price Target Difference | 21.50% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 27.41% |
| EPS Growth Forecast (3Y) | 75.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |